News | May 28, 2014

CeGaT, A Leading German Diagnostics Laboratory, Selects N-Of-One To Provide Clinical Interpretation For Next-Generation Sequencing Tests

LEXINGTON, MASS.--(BUSINESS WIRE)--

N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with CeGaT, a leading, innovative laboratory in Germany that provides a wide array of molecular diagnostics tests. Under this agreement, N-of-One will provide clinical interpretation for CeGaT’s next-generation sequencing (NGS) tests done for cancer patients. Financial terms of the agreement are not disclosed.

CeGaT has developed a next-generation sequencing panel to analyze more than 550 cancer-relevant genes in a tumor sample simultaneously. Knowledge about the relevant mutations in a tumor helps clinicians select the most effective therapeutic strategies. CeGaT is partnering with N-of-One to provide high quality, up-to-date interpretation of mutations with very rapid turnaround times.

N-of-One’s clinical interpretation provides the relevant biological and clinical knowledge related to the mutation profile of a tumor identified by sequencing. This in turn links the knowledge to relevant therapeutic strategies, in some cases including clinical trials.

“CeGaT offers a new tool for tumor diagnostics that helps oncologists decide on the most effective therapeutic options for a patient,” said Saskia Biskup, MD, PhD, CeGaT co-founder and Managing Director. “N-of-One will provide the fast, scalable and high quality interpretation of variants needed to meet demand.”

“CeGaT’s industry-leading molecular diagnostics solutions, coupled with N-of-One’s deep expertise in clinical interpretation in oncology, will enable broader patient access to personalized medicine for cancer patients in a cost-effective manner.” said Chris Cournoyer, CEO of N-of-One.

About CeGaT GmbH

CeGaT offers a wide range of services for sequencing and analysis of genetic information for individuals and families to identify molecular alterations in genomic code. Upon identification of genetic variants, CeGaT provides comprehensive clinical interpretation for improved diagnosis, prognosis and treatment.

The services include Diagnostic Panels, Tumor Diagnostics, Exome Sequencing, Single Gene Testing and Pharmacogenetics. The Diagnostic Panels use state of the art next-generation sequencing (NGS) technology to simultaneously analyze all known genes associated with a specific disease. This service is available for a broad range of diseases.

For their ideas and concepts, CeGaT was awarded the two prestigious entrepreneurship prizes in Germany: the German Founders Prize as best start-up company 2011 and the "EY Entrepreneur of the year 2013".

CeGaT GmbH was founded in 2009 by Dr. Saskia Biskup and Dr. Dirk Biskup located in Tübingen. Today, the CeGaT team includes more than 65 employees.

For more information, please visit www.cegat.com.

About N-of-One

N-of-One, a leader in precision medicine for oncology, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinical insights and therapeutic options. N-of-One’s team of experts has interpreted more than 7,000 tumors for oncologists and patients worldwide, through partnerships to provide clinical interpretation for leading diagnostic companies such as CeGaT, through agreements with provider networks such as Mayo Clinic, Cedars-Sinai, Dartmouth and Fox Chase Cancer Center, directly to oncologists and through employee access benefit programs such as Life Technologies. N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.


Copyright Business Wire 2014

Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers